PT - JOURNAL ARTICLE AU - Karoline Leuzinger AU - Tim Roloff AU - Rainer Gosert AU - Kirstin Sogaard AU - Klaudia Naegele AU - Katharina Rentsch AU - Roland Bingisser AU - Christian H. Nickel AU - Hans Pargger AU - Stefano Bassetti AU - Julia Bielicki AU - Nina Khanna AU - Sarah Tschudin Sutter AU - Andreas Widmer AU - Vladimira Hinic AU - Manuel Battegay AU - Adrian Egli AU - Hans H. Hirsch TI - Epidemiology of SARS-CoV-2 Emergence Amidst Community-Acquired Respiratory Viruses AID - 10.1101/2020.07.07.20148163 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.07.20148163 4099 - http://medrxiv.org/content/early/2020/07/08/2020.07.07.20148163.short 4100 - http://medrxiv.org/content/early/2020/07/08/2020.07.07.20148163.full AB - Background SARS-CoV-2 emerged in China in December 2019 as new cause of severe viral pneumonia (CoVID-19) reaching Europe by late January 2020. We validated the WHO-recommended assay and describe the epidemiology of SARS-CoV-2 and community-acquired respiratory viruses (CARVs).Methods Naso-oropharyngeal swabs (NOPS) from 7663 individuals were prospectively tested by the Basel-S-gene and the WHO-based E-gene-assay (Roche) using Basel-N-gene-assay for confirmation. CARVs were tested in 2394 NOPS by multiplex-NAT, including 1816 together with SARS-CoV-2.Results Basel-S-gene and Roche-E-gene-assays were concordant in 7475 cases (97.5%) including 825 (11%) positive samples. In 188 (2.5%) discordant cases, SARS-CoV-2 loads were significantly lower than in concordant positive ones and confirmed in 105 NOPS. Adults were more likely to test positive for SARS-CoV-2, while children were more likely to test CARV-positive. CARV co-infections with SARS-CoV-2 occurred in 1.8%. SARS-CoV-2 replaced other CARVs within 3 weeks reaching 48% of all detected respiratory viruses followed by rhino/enterovirus (13%), influenzavirus (12%), coronavirus (9%), respiratory syncytial (6%) and metapneumovirus (6%).Conclusions The differential diagnosis for respiratory infections was broad during the early pandemic, affecting infection control and treatment decisions. We discuss the role of pre-existing immunity and competitive CARV replication for the epidemiology of SARS-CoV-2 infection among adults and children.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study has been funded by the University of Basel appointment grant to HHH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to good laboratory practice and in accordance with the Declaration of Helsinki and national and institutional standards and was approved by the ethical committee (EKNZ 2020-00769).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred to in the manuscript are available